author-photo

Elizabeth Lenihan

Cork University Hospital

6

Papers

17

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study

2019 Blood Advances
Show All
- Source
- Cite
- Save
Citations (15)
Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

2017 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

2016 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Treatment of BRAF inhibitor-induced hyperkeratosis

2013 Acta Oncologica
Show All
- Source
- Cite
- Save
Citations (2)